Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,778
datasets available to search
ShareScore release 0.9.0
Dataset results
34,778 results for “Diseases”
DOCUMENTED HUMAN OSTEOLOGICAL COLLECTIONS AS BIOBANKS: RELEVANCE FOR RARE DISEASES IDENTIFICATION IN THE PAST
<p><em><strong>Presented at: 23rd Paleopathology Association European Meeting, Vilnius, Lituânia, 25-29 Agosto. Paleopathology Association European (Vilnius, Lituânia)</strong></em></p> <p>Disease identification in paleopathology relies on the exercise of differential diagnosis, and interpretation. Only a few diseases leave macroscopic pathognomonic traits in bone, and even in cases where microscopic, biochemical and biomolecular analyses are used, diagnosis is invariably inconclusive. Additionally, bone response to a variety of etiologies tends to be homogenous, with mosaic pattern(s) of bone formation and destruction. Therefore, access to pathological cases from human remains of Documented Human Osteological Collections (DHOC) is an exceptional approach. The access to biographical data of the individuals incorporated into the DHOC includes the cause of death, ancestry, sex, age, clinical data and other information akin to clinical data allowing for the possibility of hypothesis-driven research in which bones changes correlate with causes of death - hence providing tested and informed differential diagnosis. In this sense, DHOC may be viewed as a biobank equivalent, i.e. biorepository that stores biological samples for research in the identification of bone changes related to diseases associated with clinical and personal data. This paper will explore known cases of diseases’ diagnoses, such as lepra, neoplasias, tuberculosis, syphilis, and diffuse idiopathic skeletal hyperostosis that have used DHOC as diagnostic testing grounds, to explore bone changes and methodological advancements. The paper also introduces the idea of DHOC as biobanks dedicated to the study of rare diseases, as rarely reposted diseases, in paleopathology. </p> <p><strong>Keywords: </strong>Health, biorepository, biobanks, DHOC, differential diagnosis</p>
Data from: Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson's disease: A retrospective study
<p><span>Patients with Parkinson's disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD.</span></p> <p><span>CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics.</span></p> <p><span>We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics.</span></p> <p><span>This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD.</span><span> Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.</span></p>
Retinal Fundus Multi-Disease Image Dataset (RFMiD) 2.0
<p>Retinal Fundus Multi-disease Image Dataset (RFMiD 2.0) is an auxiliary dataset to our previously published dataset. RFMiD 2.0 is a more challenging dataset to research society to develop the computer-based disease diagnosis system. Diabetic Retinopathy, cataracts, and refractive error in the eye are leading diseases that may lead to permanent vision loss more frequently. Therefore, developing an AI-based model to classify these diseases is useful for ophthalmologists. This dataset consists of 860 images of frequently and rarely observed 51 diseases. However, some images are labeled with multiple diseases. This dataset is useful for the research and development of AI-based medical healthcare systems in ophthalmology. </p>
Conservation measures or hotspots of disease transmission? Agri-environment schemes can reduce disease prevalence in pollinator communities
<p><span>Insects are under pressure from agricultural intensification. To protect pollinators, conservation measures such as the EU agri-environment schemes (AES) promote planting wildflowers along fields. However, this can potentially alter disease ecology by serving as transmission hubs or by diluting infections. We tested this by measuring plant-pollinator interactions and virus infections (DWV-A, DWV-B and ABPV) across pollinator communities in agricultural landscapes over a year. AES had a direct effect on DWV-B, reducing prevalence and load in honeybees, with a tentative general dilution effect on load in early summer. DWV-A prevalence was reduced both under AES and with increasing niche overlap between competent hosts, likely via a dilution effect. In contrast, AES had no impact on ABPV; its prevalence was driven by the proportion of bumblebees in the community. Epidemiological differences were also reflected in the virus phylogenies, with DWV-B showing recent rapid expansion, while DWV-A and ABPV showed slower growth rates and geographic population structure. Phylogenies indicate that all three viruses freely circulate across their host populations. Our study illustrates how complex interactions between environmental, ecological and evolutionary factors may influence wildlife disease dynamics. Supporting pollinator nutrition can mitigate the transmission of important bee diseases, providing an unexpected boost to pollinator conservation.</span></p>
Speos: An ensemble graph representation framework to predict core genes for complex diseases (Datasets)
<p>the "data.tar.gz" tarball contains the unprocessed or minimally processed data used by Speos. If you intend to use the framework or want to inspect the data, download this part of the dataset.</p> <p>The "final_datasets.tar.gz" tarball contains tsv-formatted, processed data matrices which are directly used as input features for the ensemble models. </p> <p>There are two tsv-files per disease, one labeled "normal", which contains the p input features alongside the gene identifiers and a column which indicates if the gene is labeled as Mendelian or not, and another file labeled "with_n2v_vectors", which also contains the 100-dimensional vectors produced by Node2Vec so the N2V+MLP method can be reproduced with the exact same parameters. </p> <p>All files contain a header row which describes the column and no index column.</p> <p>The "model_parameters.tar.gz" tarball contains the model parameters for all ensemble models used to produce the candidate genes.</p>
The Nova Scotia Disease Knowledge Graph
<p>Nova Scotia's government has an abundance of resources in terms of data and information. All this data has been collected and stored on the NSOD portal (<a href="https://data.novascotia.ca/">https://data.novascotia.ca</a>) in the form of datasets. The Nova Scotia Open Data Portal was built and managed by Socrata API (<a href="https://dev.socrata.com/">https://dev.socrata.com</a>). We transformed the disease-related datasets of Nova Scotia Open Data into RDF, enriched them by disease ontology, and it is available to be used under the MIT licence.</p> <p>- Added DBpedia linking</p>
Barriers to home exercise for patients with Parkinson's disease – a qualitative study
<p><strong>Objective</strong>: This study aimed to explore the barriers to home exercise for patients with Parkinson's disease (PwPDs) and provide guidelines for healthcare providers (HcPs) to build and implement home exercise strategies for PwPDs.</p> <p><strong>Design</strong>: A qualitative descriptive method was used. Semi-structured interviews were conducted and thematic analysis was employed.</p> <p><strong>Setting</strong>: The study was conducted in the Department of Neurology at a Grade 3 Class A general hospital in China.</p> <p><strong>Participants</strong>: A total of 22 participants were interviewed, including 10 PwPDs, seven caregivers, two nurses, one head nurse, and two Parkinson's clinicians.</p> <p><strong>Results</strong>: Five themes were identified in this analysis. (1) Psychosomatic stress and low activity; (2) lack of early rehabilitation authorisation; (3) poor "flow" state of home exercise; (4) inaccessibility of continued service; (5) sociocultural impact on family coping.</p> <p><strong>Conclusion</strong>: PwPDs, caregivers, and specialised medical staff raised the challenges faced by patients' home exercises from different perspectives. Interventions can improve services and integrate resources through the management of multi-disciplinary, early rehabilitation authorisation, exercise experience, continuous service mode, and family coping strategies under different cultures to gradually adjust the home exercise behaviour of PwPDs.</p>
KidDO project update - quantitative proteomic and metabolomic analysis of five mouse models with chronic kidney disease
<p>Chronic kidney disease (CKD) is one of the most deadly diseases faced by patients and is a major global health and socioeconomic burden.CKD increases cardiovascular morbidity and premature mortality and decreases quality of life. Hypertension (HTN) and type 2 diabetes mellitus (T2DM), which are reaching epidemic levels, are major risk factors for CKD. CKD diagnosis and progression is based on estimated GFR (eGFR) and urinary albumin excretion. However, eGFR only has a predictive value in advanced disease and there is risk of progressive CKD in non-albuminuric individuals. Thus, there is an urgent need for new approaches for early detection of the most “at risk” individuals and identification of CKD signatures to aid in designing novel drugs and preventive measures that could ameliorate progression of CKD.</p> <p>Our overarching goal is to identify metabolites that predict kidney cell phenotypes during CKD and how crosstalk of these metabolites with the proteome drive CKD progression. We will integrate metabolomics and proteomic information from animal models of CKD with human CKD patient biopsies to identify common signatures in the tubulointerstitium that correlate with human pathophysiology.</p> <p>Here we provide quantitative proteomic and metabolomic datasets, as well as plasma and urine electrolyte measurements on five CKD mouse models.</p>
Disease matrix
<p>Matrix juxtaposing 125 zoonotic diseases with disease-specific arguments on several exclusion criteria ((i) the pathogen is merely food- or waterborne, (ii) the pathogen is only relevant due to its antimicrobial resistance, (iii) the pathogen is not zoonotic or a zoonotic potential is very unlikely/not scientifically proven, (iv) the pathogen has no or only negligible public health impact, (v) the pathogen poses no or only negligible risk of introduction into the EU (i.e. reservoirs or vectors are not present), (vi) the pathogen has no animal host, (vii) the exact pathogen species is not mentioned) in the context of the initiative ‘CP-g-22-04.01 Direct grants to Member States’ authorities’ of the EU4Health Programme</p>
Questionnaire for assessing diseases against pathogen-related criteria
<p>Excel file for the questionnaire survey on zoonotic diseases provided to Member States in the context of the initiative 'CP-g-22-04.01 Direct grants to Member States’ authorities’ of the EU4Health Programme</p>
Data for "Brain cell-type shifts in Alzheimer's disease, autism and schizophrenia interrogated using methylomics and genetics"
<p>Data for "Genetic and methylomic interrogation of brain cell-type shifts in autism, schizophrenia, and Alzheimer’s disease" (Yap et al. 2023).</p> <p>Source data from ROSMAP, LIBD and UCLA_ASD post-mortem brain datasets.</p> <p>This data repository contains 3 files:</p> <p><strong>220819_Supplementary_Tables.xlsx</strong></p> <p>Supplementary Tables for the manuscript:</p> <ol> <li>Supplementary Table 1: Comparison of CTP deconvolution methods in the ROSMAP dataset. mcc* denotes methylCC deconvolution; sSV* denotes smartSVA; h* indicates Houseman using array reference data; hseq* indicates Houseman with sequencing reference data; celfie* indicates CelFIE (and includes an output titled "unknown1"); VAEe* indicates variational autoencoder embeddings.</li> <li>Supplementary Table 2: Comparison of CTP deconvolution methods in the LIBD dataset. mcc* denotes methylCC deconvolution; sSV* denotes smartSVA; h* indicates Houseman using array reference data; hseq* indicates Houseman with sequencing reference data; celfie* indicates CelFIE (and includes an output titled "unknown1"); VAEe* indicates variational autoencoder embeddings.</li> <li>Supplementary Table 3: Comparison of CTP deconvolution methods in the UCLA_ASD dataset. mcc* denotes methylCC deconvolution; sSV* denotes smartSVA; h* indicates Houseman using array reference data; hseq* indicates Houseman with sequencing reference data; celfie* indicates CelFIE (and includes an output titled "unknown1"); VAEe* indicates variational autoencoder embeddings.</li> <li>Supplementary Table 4: Deconvolved brain CTPs (raw), with covariates.</li> <li>Supplementary Table 5: Deconvolved brain CTPs (clr-transform, offset 1e-3), with covariates and raw PGS for all ancestries. Comp* indicates compositionally-aware principal components of the CTP data; *pgs_raw indicates PGS calculated for using genotyping across all ancestries. This table has a total of n=1,098 across all ancestries, including n=885 EUR. After applying a rel<0.05 threshold on the n=885 EUR, there were n=878 EUR which were used in the PGS analysis so that population stratification PCs did not simply capture family structure.</li> <li>Supplementary Table 6: Deconvolved brain CTPs (clr-transform, offset 1e-3), with covariates and standardised PGS for n=878 Europeans. *pgs_raw indicates unstandardised PGS, PC* indicates genotyping PCs within the European dataset, *_PGS indicates standardised PGS within the European subset.</li> <li>Supplementary Table 7: Deconvolved brain CTPs (clr-transform, offset 1e-3), adjusted for oligodendrocyte proportions, with covariates.</li> <li>Supplementary Table 8: Deconvolved brain CTPs (raw), adjusted for oligodendrocyte proportions, with covariates.</li> </ol> <p><strong>20220108_maf05_gwas_ctp.tar.gz</strong></p> <p>GWAS summary statistics for the 7 brainCTPs (clr-transformed): Exc, Inh, Astro, Endo, Micro, Oligo, OPC</p> <p>METAL output format:<br> MarkerName: SNP<br> Allele1<br> Allele2<br> Freq1: Allele1 frequency<br> FreqSE: frequency standard error<br> MinFreq: minimum Allele1 frequency in meta-analysis<br> MaxFreq: maximum Allele1 frequency in meta-analysis<br> Effect: effect size<br> StdErr: standard error of effect size<br> P-value: calculated in inverse variance weighted meta-analysis<br> Direction: directions of effects across the 3 datasets<br> HetISq: heterozygosity I-squared<br> HetChiSq: heterozygosity chi-squared<br> HetDf: heterozygosity degress of freedom<br> HetPVal: heterozygosity test p-value</p> <p><strong>20220108_maf05_gwas_ctp_pc.tar.gz</strong></p> <p>GWAS summary statistics for the 5 CTP_PCs</p> <p>METAL output format (see above)</p> <p> </p> <p><strong>Source data</strong>:</p> <p>ROSMAP: Raw methylation .idat files were obtained from Synapse accession syn7357283. Whole genome sequencing .vcf files (variants jointly called with MSBB and Mayo studies) were obtained from Synapse accession syn11707420.</p> <p>LIBD: Raw methylation .idat files were obtained from GEO accession GSE74193. SNP genotypes were downloaded from dbGaP accession phs000417.v2.p1.</p> <p>UCLA-ASD: The processed methylation beta matrix was downloaded from Synapse accession syn8263588. SNP genotypes were downloaded from Synapse accession syn10537134.</p> <p>GWAS summary statistics are available at: 10.5281/zenodo.7604231</p> <p>Code is available on GitHub: gandallab/brain_CTP_deconv</p>
Raw Data for the article: Clinical Insights to Complete and Incomplete Surgical Revascularization in Atrial Fibrillation and Multivessel Coronary Disease
<p><strong>Objectives: </strong>Although endorsed by international guidelines, complete revascularization (CR) with Coronary Artery Bypass Grafting (CABG) remains underused. In higher-risk patients such as those with pre-operative atrial fibrillation (AF), the effects of CR are not well studied.</p> <p><strong>Methods: </strong>We analyzed patients' data from the HEIST (HEart surgery In AF and Supraventricular Tachycardia) registry. Between 2012 and 2020 we identified 4770 patients with pre-operative AF and multivessel coronary artery disease who underwent isolated CABG. We divided the cohort according to the completeness of the revascularization and used propensity score matching (PSM) to minimize differences between baseline characteristics. The primary endpoint was all-cause mortality.</p> <p><strong>Results: </strong>Median follow-up was 4.7 years [interquartile range (IQR) 2.3-6.9]. PSM resulted in 1,009 pairs of complete and incomplete revascularization. Number of distal anastomoses varied, accounting for 3.0 + -0.6 vs. 1.7 + -0.6, respectively. Although early (< 24 h) and 30-day post-operative mortalities were not statistically different between non-CR and CR patients [Odds Ratio (OR) and 95% Confidence Intervals (CIs): 1.34 (0.46-3.86); <em>P</em> = 0.593, Hazard Ratio (HR) and 95% CIs: 0.88 (0.59-1.32); <em>P</em> = 0.542, respectively] the long term mortality was nearly 20% lower in the CR cohort [HR (95% CIs) 0.83 (0.71-0.96); <em>P</em> = 0.011]. This benefit was sustained throughout subgroup analyses, yet most accentuated in low-risk patients (younger i.e., < 70 year old, with a EuroSCORE II < 2%, non-diabetic) and when off-pump CABG was performed.</p> <p><strong>Conclusion: </strong>Complete revascularization in patients with pre-operative AF is safe and associated with improved survival. Particular survival benefit with CR was observed in low-risk patients undergoing off-pump CABG.</p>
Raw Data for the article: Risk factors for bile leakage after liver resection for neoplastic disease
<p>Biliary leakage (BL) remains the most frequent and feared complication after hepatoresective surgery. Placement of the abdominal drainage at the end of liver surgery remains controversial due to the delicate balance between risks and potential benefits in case of BL. The study was aimed to detect possible risk factors for BL occurrence after liver surgery. We enrolled all oncologic patients who underwent liver resection from June 2016 to March 2021. BL was diagnosed according to the ISGLS definition. We have examined demographic characteristics of the patients, type of neoplasia, presence of cirrhosis, neoadjuvant chemotherapy and type of intervention. Uni- and multivariable analyses were performed to assess the predictive value of potential predictor of BL. A total of 379 patients were enrolled in the study, 16 (4.2%) of which developed BL. Among others, at univariate analysis the occurrence of BL was found to be associated with bilio-digestive anastomosis (OR: 9.75, C.I. 2.7-34.7, p < 0.001) and neoadjuvant chemotherapy (OR: 0.09, C.I 0.01,-0.88, p = 0.039). Multivariable analysis selected the body mass index (OR: 1.21, 95%C.I.: 1.04-1.41, p = 0.015), anatomical resection (OR: 8.35, 95% C.I.: 2.01-34.74, p = 0.004), and blood loss (OR: 1.09, 95%C.I.: 1.05-1.13, p < 0.001). Identification of patients at greater risk of BL can help in the choice of positioning the drainage at the end of liver surgery.</p>
DATASET RELATED TO ARTICLE "MISSENSE MUTATION IN ATXN2 GENE (C.2860C > T) IN AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT WITH AGGRESSIVE DISEASE PHENOTYPE"
<p><strong>NGS_analysis PERFORMED AT fONDAZIONE BESTA AND CARRIED OUT AS PART OF THE STUDY MENTIONED AT TITLE</strong></p>
Data for: Deep brain stimulation in early-stage Parkinson disease
<p><strong>Objective</strong>: To report 5-year outcomes from the subthalamic nucleus (STN) deep brain stimulation (DBS) in early-stage Parkinson disease (PD) pilot clinical trial.</p> <p><strong>Methods</strong>: The pilot was a prospective, single-blind clinical trial that randomized patients with early-stage PD (Hoehn & Yahr II off medications) to receive bilateral STN DBS plus optimal drug therapy (ODT) vs ODT alone (IDEG050016, NCT0282152, IRB040797). Participants who completed the 2-year trial participated in this observational follow-up study, which included annual outpatient visits through 5 years. This analysis includes 28 patients who were taking PD medications for 6 months to 4 years at enrollment. Outcomes were analyzed using both proportional odds logistic regression and linear mixed effects models.ResultsEarly STN DBS + ODT participants required lower levodopa equivalent daily doses (p = 0.04, β = −240 mg, 95% confidence interval [CI] −471 to −8) and had 0.06 times the odds of requiring polypharmacy at 5 years compared to early ODT participants (p = 0.01, odds ratio [OR] 0.06, 95% CI 0.00 to 0.65). The odds of having worse rest tremor for early STN DBS + ODT participants were 0.21 times those of early ODT participants (p < 0.001, OR 0.21, 95% CI 0.09 to 0.45). The safety profile was similar between groups.</p> <p><strong>Conclusions</strong>: These results suggest that early DBS reduces the need for and complexity of PD medications while providing long-term motor benefit over standard medical therapy. Further investigation is warranted, and the Food and Drug Administration has approved the conduct of a prospective, multicenter, pivotal clinical trial of DBS in early-stage PD (IDEG050016).</p> <p><strong>Classification of evidence</strong>: This study provides Class II evidence that DBS implanted in early-stage PD decreases the risk of disease progression and polypharmacy compared to optimal medical therapy alone.</p>
Data for: Sex-biased infections scale to population impacts for an emerging wildlife disease
<p>Demographic factors are fundamental in shaping infectious disease dynamics. Aspects of populations that create structure, like age and sex, can affect patterns of transmission, infection intensity and population outcomes. However, studies rarely link these processes from individual to population-scale effects. Moreover, the mechanisms underlying demographic differences in disease are frequently unclear. Here, we explore sex-biased infections for a multi-host fungal disease of bats, white-nose syndrome, and link disease-associated mortality between sexes, the distortion of sex ratios, and the potential mechanisms underlying sex differences in infection. We collected data on host traits, infection intensity, and survival of five bat species at 42 sites across seven years. We found females were more infected than males for all five species. Females also had lower apparent survival over winter and accounted for a smaller proportion of populations over time. Notably, female-biased infections were evident by early hibernation and likely driven by sex-based differences in autumn mating behavior. Male bats were more active during autumn which likely reduced replication of the cool-growing fungus. Higher disease impacts in female bats may have cascading effects on bat populations beyond the hibernation season by limiting recruitment and increasing the risk of Allee effects.</p>
Data for: Capturing complex interactions in disease ecology with simplicial sets
<p>Here we provide archived code for: Code for Capturing Complex Interactions in Disease Ecology with Simplicial Sets. Ecology Letters. The code provided can be used to generate the figures used in the manuscript as well as to generate appendix 3 in the supplementary materials. In the paper, we describe how higher-order network approaches can be applied in disease ecology research. We explain <em>what</em> simplicial sets are; <em>why</em> their use would be beneficial in different subject areas; <em>where</em> these areas are: social, transmission, movement/spatial and ecological networks; and <em>when</em> using them would help most in each context. To demonstrate their application, we develop a novel approach to identify how pathogens persist within a host population (see code for Appendix 3 in this repository). We also provide an overview of <em>how</em> to use simplicial sets, highlighting specific metrics, generative models and software. Finally, we <em>synthesize</em> key research questions simplicial sets will help us answer and highlight the methodological developments required.</p>
Correlation of viral loads in disease transmission could affect early estimates of the reproduction number
<p>This dataset accompanies the an article titled, 'Correlation of viral loads in disease transmission could affect early estimates of the reproduction number', by T. Harris et al. which can be found at https://arxiv.org/abs/2211.08673.</p> <p>Abstract:</p> <p>Early estimates of the transmission properties of a newly emerged pathogen are critical to an effective public health response, and are often based on limited outbreak data. Here, we use simulations to investigate how correlations between the viral load of cases in transmission chains can affect estimates of these fundamental transmission properties. Our computational model simulates a disease transmission mechanism in which the viral load of the infector at the time of transmission influences the infectiousness of the infectee. These correlations in transmission pairs produce a population-level convergence process during which the distributions of initial viral loads in each subsequent generation converge to a steady state. We find that outbreaks arising from index cases with low initial viral loads give rise to early estimates of transmission properties that could be misleading. These findings demonstrate the potential for transmission mechanisms to affect estimates of the transmission properties of newly emerged viruses in ways that could be operationally significant to a public health response.</p> <p> </p> <p>Contents of this dataset include: </p> <ul> <li>Model code - including experiments (python3)</li> <li>Estimation code (R)</li> <li>Code used for figure production (python3 & R)</li> <li>Raw data produced from Experiments 1-3 and presented in the text (.csv & .Rdata)</li> </ul> <p>See 'README.md' in main upload folder for more information</p>
Modeling the Sequence Dependence of Differential Antibody Binding in the Immune Response to Infectious Disease
<p>Raw peptide microarray data of fluorescence intensities representing relative binding of antibodies in sera samples collected from different cohorts of patients diagnosed with a number of viral infections. Healthy controls are also included.</p> <p>Columns:</p> <p>Sequence - peptide sequence</p> <p>HCV - Hepatitis Virus C</p> <p>Dengue - Dengue virus</p> <p>WNV - West Nile Virus</p> <p>HBV - Hepatitis Virus B</p> <p>Chagas - Chagas disease</p> <p>ND - negative/healthy donor</p> <p>LowCV - low coefficient of variation</p> <p>HighCV - high coefficient of variation</p>
Data and Code for "A planetary health innovation for disease, food, and water challenges in Africa"
<p>Data and R code for both economic and non-economic analysis for the paper titled, "A planetary health innovation for disease, food, and water challenges in Africa"</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.